TY - JOUR T1 - Ximelagatran was not inferior to warfarin for preventing stroke and systemic embolism in non-valvular atrial fibrillation JF - Evidence Based Medicine JO - Evid Based Med SP - 110 LP - 110 DO - 10.1136/ebm.10.4.110 VL - 10 IS - 4 A2 - , Y1 - 2005/08/01 UR - http://ebm.bmj.com/content/10/4/110.abstract N2 - Executive Steering Committee for the SPORTIF V Investigators. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA 2005;293:690–8.OpenUrlCrossRefPubMedWeb of Science 
 
 Q In patients with non-valvular atrial fibrillation requiring long term oral anticoagulant therapy, is fixed dose oral ximelagatran non-inferior to adjusted dose warfarin for preventing stroke and systemic embolism? Clinical impact ratings GP/FP/Primary care ★★★★★☆☆ IM/Ambulatory care ★★★★★★☆ Internal medicine★★★★★★☆ Haematology ★★★★★★★ Cardiology ★★★★★★☆ Design: randomised controlled trial (Stroke Prevention using an Oral Thrombin Inhibitor in Atrial Fibrillation [SPORTIF] V). Allocation: concealed.* Blinding: blinded (clinicians, patients, and outcome assessors).* Follow-up period: mean 20 months. Setting: 409 sites in the US and Canada. Patients: 3922 patients (mean age 72y, 69% men) who had persistent or paroxysmal non-valvular atrial fibrillation and ⩾1 risk factor for stroke (eg, previous stroke, transient ischaemic attack, or systemic embolism; hypertension; left ventricular dysfunction; and age ⩾75 y or ⩾65 y with coronary disease or diabetes mellitus). … ER -